TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 156 filers reported holding TURNING POINT THERAPEUTICS I in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $5,413,000 | +171.6% | 71,942 | -3.1% | 0.00% | +100.0% |
| Q1 2022 | $1,993,000 | -65.4% | 74,233 | -38.5% | 0.00% | -50.0% |
| Q4 2021 | $5,755,000 | +133.2% | 120,638 | +224.8% | 0.00% | +100.0% |
| Q3 2021 | $2,468,000 | +283.8% | 37,143 | +350.3% | 0.00% | – |
| Q2 2021 | $643,000 | -83.7% | 8,249 | -80.3% | 0.00% | -100.0% |
| Q1 2021 | $3,953,000 | +4017.7% | 41,792 | +5217.0% | 0.00% | – |
| Q4 2020 | $96,000 | -47.8% | 786 | -62.7% | 0.00% | – |
| Q3 2020 | $184,000 | +111.5% | 2,105 | +56.9% | 0.00% | – |
| Q2 2020 | $87,000 | -69.3% | 1,342 | -78.9% | 0.00% | – |
| Q1 2020 | $283,000 | -77.7% | 6,352 | -68.8% | 0.00% | – |
| Q4 2019 | $1,269,000 | +24.5% | 20,375 | -24.9% | 0.00% | – |
| Q3 2019 | $1,019,000 | +1098.8% | 27,114 | +1196.1% | 0.00% | – |
| Q2 2019 | $85,000 | – | 2,092 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 708,233 | $44,116,000 | 18.91% |
| Corriente Advisors, LLC | 285,000 | $17,753,000 | 9.54% |
| Cormorant Asset Management, LP | 3,396,650 | $211,577,000 | 8.44% |
| Opaleye Management Inc. | 340,500 | $21,210,000 | 4.16% |
| Orbimed Advisors | 2,745,327 | $171,006,000 | 2.44% |
| Parkman Healthcare Partners LLC | 101,434 | $6,318,000 | 1.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,000 | $2,179,000 | 0.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 366,000 | $22,798,000 | 0.73% |
| Artal Group S.A. | 300,000 | $18,687,000 | 0.72% |
| DAFNA Capital Management LLC | 30,408 | $1,894,000 | 0.65% |